Navigation Links
Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility
Date:9/16/2009

CHENGDU, China, Sept. 16 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE AMEX: TPI), a manufacturer and supplier of modernized traditional Chinese medicines ("TCM") today announced that its new production facility obtained the Good Manufacturing Practices Certificate for pharmaceutical products ("GMP Certificate") from the State Food and Drug Administration ("SFDA") in China.

According to the National Medicine Administration Law of the People's Republic of China, all new pharmaceutical manufacturing facilities must pass an examination to obtain their GMP Certificates. In June 2009, the examination committee visited Tianyin Pharmaceuticals and conducted a review of management practices of its new production facility, including quality control of raw materials, manufacturing processes, and the inspection and acceptance of its finished products. Tianyin's new production facility for solid dosage drugs met all GMP standards.

"We are very pleased with the SFDA's decision to grant us the GMP certification, which is the result of hard work and dedication from our entire team," Dr. Jiang, Chairman and CEO of Tianyin Pharmaceutical Co., Inc., commented. "This certification is the final step to commencing production at our new facility and effectively tripling the capacity of our solid dosage medicines, such as Azithromycin Dispersible Tablets, Mycophenolate Mofetil Capsules, Dantong Capsules and other recently approved medicines in our portfolio. This will enable us to meet our projected 40% revenue growth for fiscal 2010 while providing the capacity to accommodate up to $100 million in annual revenues as we look toward the future."

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
2. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
3. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
4. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
5. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
6. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
7. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
8. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
9. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
10. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
11. Tianyin Pharmaceutical Appoints Three New Independent Board Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 PuraMed BioScience ® , ... of over-the-counter (OTC) medicinal and healthcare products, announced ... the company based on low market capitalization valuation. ... All Natural Product to Treat Migraine Headaches ... Prescription Competitor , Currently Available Nationwide at ...
(Date:5/23/2013)... PI’s new LPS-24 positioners are ... mm travel range with closed-loop sensor resolution up ... these new positioners the ideal choice for high ... version is also available. , More Information: ... be found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 , ...
(Date:5/23/2013)... PARK, Calif. , May 23, 2013 ... oral treatment for pain has reached an important milestone, ... trial of VBY-036 - a selective cathepsin S inhibitor. ... VBY-036 is a double-blind, randomized, placebo-controlled study designed to ... doses of VBY-036 in healthy adults. "The ...
(Date:5/23/2013)... , May 23, 2013 Z Trim ... value-added ingredients to a variety of industries, announced that ... a panel discussion at this year,s National Restaurant Association ... 2013, on behalf of the Research Chefs Association.  Chef ... Restaurants: The Good, the Bad and the Ugly," joining ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
... of ... Directors, ... its platform technology to identify and,develop compounds that promote the growth ... announced today that it has,completed a $30 million initial closing of ...
... N.J., March 10 Palatin,Technologies, Inc. (Amex: ... Phase I,clinical trial of PL-3994, a novel, long-acting ... treatment of acute,decompensated congestive heart failure (CHF). The ... single ascending dose study,in 26 healthy volunteers who ...
... leader in,developing automated molecular testing solutions, announced today ... biotechnology companies presenting,at the 28th Annual Cowen Health ... Marriott Copley Place in Boston, Massachusetts. Fareed Kureshy,President ... of the,company, its automated molecular testing platform and ...
Cached Biology Technology:BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing 2Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 2Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 3Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 4
(Date:5/24/2013)... Orleans, LA After studying noise in one French ... not noise levels exceeded municipal ordinances, Annette Hurley, PhD, ... New Orleans, and Eric Arriaga, a third-year LSUHSC doctor ... to protect their own hearing health. Their case study ... Advance for Hearing Practice Management ., "An important part ...
(Date:5/23/2013)... , Automated conserved noncoding sequence ... evolution among grasses , Within the genome of ... that undergo little change in position and sequence over ... proteins. Some of these evolutionarily stable sequences, so-called conserved ... of other genes or the condensation of chromosomes, but ...
(Date:5/23/2013)... More than 13,000 ships per year, carrying more than 284 ... generating roughly $1.8 billion dollars in toll fees for the ... than 55 million gallons of water are used from Gatun ... 2 million people living in the isthmus. , However, ... than 20 percent of the ships at sea, has demanded ...
Breaking Biology News(10 mins):Please do try this at home 2Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3
... Society for Microbiology (ASM) BD Award for Research ... Stephen Dumler, M.D., Professor, The Johns Hopkins University ... Diagnostic Systems, this award recognizes a distinguished scientist ... important applications in clinical microbiology. Dumler,s most ...
... release is available in German . ... epoch, around 115,000 years ago, there were significant climate ... from the Eemian Interglacial to the Weichselian Glacial was ... possibly at least two warming events. This is the ...
... caused more than $193 million in hospital-based medical care ... problems such as asthma and pneumonia that are triggered ... Corporation study. Researchers estimate that exposure to excessive ... emergency room visits and hospital admissions over the study ...
Cached Biology News:American Society for Microbiology honors J. Stephen Dumler 2Were short warm periods typical for transitions between interglacial and glacial epochs? 2Study finds dirty air in California causes millions worth of medical care each year 2Study finds dirty air in California causes millions worth of medical care each year 3
TNR-R2...
Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Goat anti-PITPN Class: Antibody Product Group: Miscellaneous Antibody...
Biology Products: